BioStock: Aptahem looks ahead with optimism

Aptahem, whose primary drug candidate Apta-1 is being developed as an emergency treatment targeting sepsis, has been able to make several key advances during the autumn. These include, among other things, an oversubscribed rights issue, which, together with warrants series TO 5 and TO 6 in 2021, secures capital for the final preclinical steps before studies in humans can be initiated. BioStock reached out to the company’s CEO Mikael Lindstam, to get his view on the most important progress made during the autumn. 

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/aptahem-looks-ahead-with-optimism/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se